Sinopharm approval was through assessment by experts: WHO
By Aazam Ameen
The World Health Organisation’s (WHO) Emergency Use Listing (EUL) of the Sinopharm vaccine came as a result of a rigorous and painstaking review and assessment process by independent experts from the Technical Advisory Group for Emergency Use Listing (TAG-EUL) and WHO teams, according to the WHO.
This comes after a statement made by President Gotabaya Rajapaksa’s Spokesman Kingsley Rathnayaka on Monday (10).
In the statement, President Gotabaya Rajapaksa’s Spokesman Kingsley Rathnayaka said that the WHO’s EUL of the Sinopharm vaccine was a result of the President’s online discussion with the Director General of the WHO.
“Sri Lanka received a donation of 600,000 doses of Chinese Sinopharm vaccine, which was not earlier approved by the World Health Organisation. However, as a result of a discussion President Gotabaya Rajapaksa held with the Director General of the World Health Organisation (WHO) via Zoom last Friday (7), the WHO on the same evening approved the emergency use of the Sinopharm vaccine,” Rathnayaka stated.
However, when The Morning contacted the WHO for comment, WHO Spokesperson for Media Relations Tarik Jašarević stated: “The Emergency Use Listing (EUL) of the Sinopharm Covid-19 vaccine produced by Beijing Bio-Institute of Biological Products Co. Ltd., subsidiary of China National Biotec Group (CNBG), came as a result of a rigorous and painstaking review and assessment process by independent experts from the Technical Advisory Group for Emergency Use Listing (TAG-EUL) and WHO teams.”
Jašarević also revealed that the decision to approve the Sinopharm vaccine was based on valuation of preclinical and clinical data, and manufacturing and quality control processes.